BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/10/2025 8:40:04 AM | Browse: 93 | Download: 620
 |
Received |
|
2024-08-30 09:38 |
|
Peer-Review Started |
|
2024-08-30 09:38 |
|
First Decision by Editorial Office Director |
|
2024-11-23 05:30 |
|
Return for Revision |
|
2024-11-23 05:30 |
|
Revised |
|
2024-12-07 04:07 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-12-20 03:07 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-12-20 05:59 |
|
Articles in Press |
|
2024-12-20 05:59 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-12-31 00:55 |
|
Publish the Manuscript Online |
|
2025-01-10 08:40 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Virology |
| Manuscript Type |
Editorial |
| Article Title |
Angiotensin-converting enzyme 2 and hepatic SARS-CoV-2 infection: Regulation, association, and therapeutic implications
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yu-Wei Luo, Ai-Long Huang and Kai-Fu Tang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China (General Program) |
82172915 |
| National Natural Science Foundation of China (General Program) |
81972648 |
| National Natural Science Foundation of China (General Program) |
81773011 |
| Chongqing Medical University Program for Youth Innovation in Future Medicine |
W0084 |
| Science and Technology Innovation Project of Chongqing Medical Unisversity |
|
| Chongqing Postdoctoral Science Foundation |
CSTB2023NSCQ-BHX0134 |
|
| Corresponding Author |
Kai-Fu Tang, PhD, Professor, Key Laboratory of Molecular Biology on Infectious Disease, Ministry of Education, Chongqing Medical University, No. 1 Yixueyuan Road, Yuzhong District, Chongqing 40016, China. tangkaifu@cqmu.edu.cn |
| Key Words |
Hepatic angiotensin-converting enzyme 2; SARS-CoV-2; Liver infection; Chronic liver diseases; COVID-19 treatment |
| Core Tip |
Angiotensin-converting enzyme 2 (ACE2) serves as the entry receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Jacobs et al discovered that elevated hepatic ACE2 expression during metabolic dysfunction may facilitate SARS-CoV-2 infection, which could potentially exacerbate the severity of coronavirus disease 2019 (COVID-19), suggesting ACE2 as a promising therapeutic target for COVID-19. |
| Publish Date |
2025-01-10 08:40 |
| Citation |
Luo YW, Huang AL, Tang KF. Angiotensin-converting enzyme 2 and hepatic SARS-CoV-2 infection: Regulation, association, and therapeutic implications. World J Gastroenterol 2025; 31(6): 100864 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i6/100864.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i6.100864 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
